Transcatheter tricuspid valve repair in the setting of heart failure with preserved or reduced left ventricular ejection fraction
Karl‐Patrik Kresoja,Alexander Lauten,Mathias Orban,Karl‐Philipp Rommel,Brunilda Alushi,Christian Besler,Daniel Braun,Matthias Unterhuber,Karl Stangl,Ulf Landmesser,Steffen Massberg,Holger Thiele,Jörg Hausleiter,Philipp Lurz
DOI: https://doi.org/10.1002/ejhf.1975
2020-09-02
European Journal of Heart Failure
Abstract:<section class="article-section__content"><h3 class="article-section__sub-title section1"> Aims</h3><p>Severe tricuspid regurgitation (TR) impairs prognosis in patients with left‐sided heart failure (HF) with preserved (≥50%, HFpEF) and reduced ejection fraction (<50%, HFrEF). Transcatheter tricuspid valve leaflet edge‐to‐edge repair (TTVR) potentially improves prognosis among patients with severe TR. We sought to assess the impact of left‐sided HF types on outcomes of TTVR.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Methods and Results</h3><p>In this retrospective study 71 HFpEF and 40 HFrEF patients, defined according to the European Society of Cardiology criteria, with isolated TR treated by TTVR, in two tertiary care centres, between 2016 and 2019 were analysed. The primary outcome was a composite outcome of all‐cause mortality, HF hospitalization at 12 months (median follow‐up 238[IQR175‐365]days). Additionally, a propensity score matching with a conservatively treated cohort of 914 patients with severe TR was performed.</p><p>Procedural success did not differ between HFpEF (mean age 75.9 ± 9.3 years) or HFrEF (mean age 74.7 ± 9.1 years) patients (86% vs. 78%,p = 0.299). The primary endpoint occurred more frequently in patients with HFrEF as compared to HFpEF (50 vs. 30%,p = 0.016). Procedural success was associated with a reduced occurrence of the primary endpoint among patients with HFpEF (p < 0.001) but not HFrEF (p = 0.813), while both groups showed improvement in New York Heart Association functional class (both p < 0.001).</p><p>After matching for age, EuroSCORE II, presence of an RV‐lead and systolic pulmonary artery pressure, successful TTVR was associated with lower mortality as compared to conservative therapy in HFpEF patients (p = 0.020), but not in HFrEF patients (p = 0.274).</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Conclusion</h3><p>TTVR might be a therapeutic option in patients with severe TR and HFpEF compared to conservative therapy.</p><p>This article is protected by copyright. All rights reserved.</p></section>
cardiac & cardiovascular systems